$9.42
-0.53 (-5.33%)
GOSS News2 articles
Gossamer Bio Surges on FDA Filing Update; Cash Covenant Looms
Gossamer Bio shares surged 46% on FDA feedback supporting its seralutinib NDA filing. Cash covenant and dilution risks persist.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.